TY - JOUR
T1 - Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in Asian subjects with human immunodeficiency virus 1 infection
T2 - A sub-analysis of phase 3 clinical trials
AU - Choi, Jun Yong
AU - Sungkanuparph, Somnuek
AU - Anekthananon, Thanomsak
AU - Sax, Paul
AU - DeJesus, Edwin
AU - Edelstein, Howard
AU - Nelson, Mark
AU - DeMorin, Jennifer
AU - Liu, Hui C.
AU - Swamy, Raji
AU - Bahn, Joonwoo
AU - Hwang, Sun Jin
AU - Yang, Sang Youn
AU - Ng, Christopher
AU - Piontkowsky, David
N1 - Publisher Copyright:
� 2016 by The Korean Society of Infectious Diseases | Korean Society for Chemotherapy.
PY - 2016
Y1 - 2016
N2 - The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-na�ve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-na�ve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-na�ve and ART-experienced Asian subjects.
AB - The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) were analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-na�ve and ART-experienced Asian subjects infected with human immunodeficiency virus (HIV)-1. Studies GS-US-236-102 and GS-US-236-103 were randomized, double-blind, placebo-controlled, 144-week studies conducted in ART-na�ve subjects, comparing E/C/F/TDF versus efavirenz (EFV)/F/TDF or ritonavir-boosted atazanavir (ATV+RTV) plus emtricitabine/tenofovir DF (F/TDF), respectively. Studies GS-US-236-115 and GS-US-236-121 were randomized, open-label, 96-week long conducted in ART-experienced subjects, who switched to E/C/F/TDF from ritonavir-boosted protease inhibitors (PI+RTV)+F/TDF, or non-nucleoside reverse transcriptase inhibitors (NNRTI)+F/TDF regimens. The E/C/F/TDF appeared to have sustained efficacy and safety and was well tolerated in the small number of ART-na�ve and ART-experienced Asian subjects.
UR - http://www.scopus.com/inward/record.url?scp=84992190569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84992190569&partnerID=8YFLogxK
U2 - 10.3947/ic.2016.48.3.219
DO - 10.3947/ic.2016.48.3.219
M3 - Article
AN - SCOPUS:84992190569
SN - 2093-2340
VL - 48
SP - 219
EP - 224
JO - Infection and Chemotherapy
JF - Infection and Chemotherapy
IS - 3
ER -
